ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint   

See more here